ATG/ALG联合环孢素A与环孢素A联合雄激素一线治疗输血依赖非重型再生障碍性贫血的疗效比较:单中心回顾性研究

OBJECTIVE: To determine whether cyclosporine A (CsA) plus androgens was as effective as the current standard immunosuppressive therapy (IST) for transfusion-dependent nonsevere aplastic anemia (TD-NSAA). METHODS: The records of 125 consecutive TD-NSAA patients who were treated between Aug. 2007 and...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial office of Chinese Journal of Hematology 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7348506/
https://www.ncbi.nlm.nih.gov/pubmed/27995878
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2016.11.004
_version_ 1783556840976547840
collection PubMed
description OBJECTIVE: To determine whether cyclosporine A (CsA) plus androgens was as effective as the current standard immunosuppressive therapy (IST) for transfusion-dependent nonsevere aplastic anemia (TD-NSAA). METHODS: The records of 125 consecutive TD-NSAA patients who were treated between Aug. 2007 and Sept. 2014, with either CsA plus androgen or ALG/ATG plus CsA regimen were reviewed. The 3-month and 6-month hematologic responses and survival were evaluated. RESULTS: There were 125 TD-NSAA patients (70 were male and 55 female, 1.25∶1). Median age was 27 (6–66) years. There was no significant difference in early mortality between 48 treated by ATG/ALG plus CsA and 77 by CsA plus androgen patients (1/48 vs 0/77, P=0.384). Both the total hematologic response and the better hematological response rates at 3-month (70.8% vs 45.5%, P=0.006 and 27.1% vs 10.4%, P=0.015, respectively) and 6-month (75.0% vs 55.8%, P=0.031 and 41.7% vs 22.1% P =0.020, respectively) after treatment were much higher in the standard IST group than that in CsA plus androgen group. The median time to transfusion independent of 36.5 (0–149) days in the standard IST group was significantly shorter than 98 (14–180) days in CsA plus androgen group (P<0.001). Survival was comparable between the two groups (97.9% vs 100.0%, P=0.227). It was superior (71.2% vs 59.5%) but not significantly (P=0.227) in event-free survival in standard IST group. CONCLUSION: CsA plus androgen was inferior to the standard IST of ATG/ALG and CsA regimen in treating TD-NSAA in terms of the hematologic response and the quality of response, despite of comparable short-term survival.
format Online
Article
Text
id pubmed-7348506
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Editorial office of Chinese Journal of Hematology
record_format MEDLINE/PubMed
spelling pubmed-73485062020-07-16 ATG/ALG联合环孢素A与环孢素A联合雄激素一线治疗输血依赖非重型再生障碍性贫血的疗效比较:单中心回顾性研究 Zhonghua Xue Ye Xue Za Zhi 论著 OBJECTIVE: To determine whether cyclosporine A (CsA) plus androgens was as effective as the current standard immunosuppressive therapy (IST) for transfusion-dependent nonsevere aplastic anemia (TD-NSAA). METHODS: The records of 125 consecutive TD-NSAA patients who were treated between Aug. 2007 and Sept. 2014, with either CsA plus androgen or ALG/ATG plus CsA regimen were reviewed. The 3-month and 6-month hematologic responses and survival were evaluated. RESULTS: There were 125 TD-NSAA patients (70 were male and 55 female, 1.25∶1). Median age was 27 (6–66) years. There was no significant difference in early mortality between 48 treated by ATG/ALG plus CsA and 77 by CsA plus androgen patients (1/48 vs 0/77, P=0.384). Both the total hematologic response and the better hematological response rates at 3-month (70.8% vs 45.5%, P=0.006 and 27.1% vs 10.4%, P=0.015, respectively) and 6-month (75.0% vs 55.8%, P=0.031 and 41.7% vs 22.1% P =0.020, respectively) after treatment were much higher in the standard IST group than that in CsA plus androgen group. The median time to transfusion independent of 36.5 (0–149) days in the standard IST group was significantly shorter than 98 (14–180) days in CsA plus androgen group (P<0.001). Survival was comparable between the two groups (97.9% vs 100.0%, P=0.227). It was superior (71.2% vs 59.5%) but not significantly (P=0.227) in event-free survival in standard IST group. CONCLUSION: CsA plus androgen was inferior to the standard IST of ATG/ALG and CsA regimen in treating TD-NSAA in terms of the hematologic response and the quality of response, despite of comparable short-term survival. Editorial office of Chinese Journal of Hematology 2016-11 /pmc/articles/PMC7348506/ /pubmed/27995878 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2016.11.004 Text en 2016年版权归中华医学会所有 http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal.
spellingShingle 论著
ATG/ALG联合环孢素A与环孢素A联合雄激素一线治疗输血依赖非重型再生障碍性贫血的疗效比较:单中心回顾性研究
title ATG/ALG联合环孢素A与环孢素A联合雄激素一线治疗输血依赖非重型再生障碍性贫血的疗效比较:单中心回顾性研究
title_full ATG/ALG联合环孢素A与环孢素A联合雄激素一线治疗输血依赖非重型再生障碍性贫血的疗效比较:单中心回顾性研究
title_fullStr ATG/ALG联合环孢素A与环孢素A联合雄激素一线治疗输血依赖非重型再生障碍性贫血的疗效比较:单中心回顾性研究
title_full_unstemmed ATG/ALG联合环孢素A与环孢素A联合雄激素一线治疗输血依赖非重型再生障碍性贫血的疗效比较:单中心回顾性研究
title_short ATG/ALG联合环孢素A与环孢素A联合雄激素一线治疗输血依赖非重型再生障碍性贫血的疗效比较:单中心回顾性研究
title_sort atg/alg联合环孢素a与环孢素a联合雄激素一线治疗输血依赖非重型再生障碍性贫血的疗效比较:单中心回顾性研究
topic 论著
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7348506/
https://www.ncbi.nlm.nih.gov/pubmed/27995878
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2016.11.004
work_keys_str_mv AT atgalgliánhéhuánbāosùayǔhuánbāosùaliánhéxióngjīsùyīxiànzhìliáoshūxuèyīlàifēizhòngxíngzàishēngzhàngàixìngpínxuèdeliáoxiàobǐjiàodānzhōngxīnhuígùxìngyánjiū
AT atgalgliánhéhuánbāosùayǔhuánbāosùaliánhéxióngjīsùyīxiànzhìliáoshūxuèyīlàifēizhòngxíngzàishēngzhàngàixìngpínxuèdeliáoxiàobǐjiàodānzhōngxīnhuígùxìngyánjiū
AT atgalgliánhéhuánbāosùayǔhuánbāosùaliánhéxióngjīsùyīxiànzhìliáoshūxuèyīlàifēizhòngxíngzàishēngzhàngàixìngpínxuèdeliáoxiàobǐjiàodānzhōngxīnhuígùxìngyánjiū
AT atgalgliánhéhuánbāosùayǔhuánbāosùaliánhéxióngjīsùyīxiànzhìliáoshūxuèyīlàifēizhòngxíngzàishēngzhàngàixìngpínxuèdeliáoxiàobǐjiàodānzhōngxīnhuígùxìngyánjiū
AT atgalgliánhéhuánbāosùayǔhuánbāosùaliánhéxióngjīsùyīxiànzhìliáoshūxuèyīlàifēizhòngxíngzàishēngzhàngàixìngpínxuèdeliáoxiàobǐjiàodānzhōngxīnhuígùxìngyánjiū
AT atgalgliánhéhuánbāosùayǔhuánbāosùaliánhéxióngjīsùyīxiànzhìliáoshūxuèyīlàifēizhòngxíngzàishēngzhàngàixìngpínxuèdeliáoxiàobǐjiàodānzhōngxīnhuígùxìngyánjiū
AT atgalgliánhéhuánbāosùayǔhuánbāosùaliánhéxióngjīsùyīxiànzhìliáoshūxuèyīlàifēizhòngxíngzàishēngzhàngàixìngpínxuèdeliáoxiàobǐjiàodānzhōngxīnhuígùxìngyánjiū
AT atgalgliánhéhuánbāosùayǔhuánbāosùaliánhéxióngjīsùyīxiànzhìliáoshūxuèyīlàifēizhòngxíngzàishēngzhàngàixìngpínxuèdeliáoxiàobǐjiàodānzhōngxīnhuígùxìngyánjiū
AT atgalgliánhéhuánbāosùayǔhuánbāosùaliánhéxióngjīsùyīxiànzhìliáoshūxuèyīlàifēizhòngxíngzàishēngzhàngàixìngpínxuèdeliáoxiàobǐjiàodānzhōngxīnhuígùxìngyánjiū
AT atgalgliánhéhuánbāosùayǔhuánbāosùaliánhéxióngjīsùyīxiànzhìliáoshūxuèyīlàifēizhòngxíngzàishēngzhàngàixìngpínxuèdeliáoxiàobǐjiàodānzhōngxīnhuígùxìngyánjiū
AT atgalgliánhéhuánbāosùayǔhuánbāosùaliánhéxióngjīsùyīxiànzhìliáoshūxuèyīlàifēizhòngxíngzàishēngzhàngàixìngpínxuèdeliáoxiàobǐjiàodānzhōngxīnhuígùxìngyánjiū
AT atgalgliánhéhuánbāosùayǔhuánbāosùaliánhéxióngjīsùyīxiànzhìliáoshūxuèyīlàifēizhòngxíngzàishēngzhàngàixìngpínxuèdeliáoxiàobǐjiàodānzhōngxīnhuígùxìngyánjiū
AT atgalgliánhéhuánbāosùayǔhuánbāosùaliánhéxióngjīsùyīxiànzhìliáoshūxuèyīlàifēizhòngxíngzàishēngzhàngàixìngpínxuèdeliáoxiàobǐjiàodānzhōngxīnhuígùxìngyánjiū
AT atgalgliánhéhuánbāosùayǔhuánbāosùaliánhéxióngjīsùyīxiànzhìliáoshūxuèyīlàifēizhòngxíngzàishēngzhàngàixìngpínxuèdeliáoxiàobǐjiàodānzhōngxīnhuígùxìngyánjiū
AT atgalgliánhéhuánbāosùayǔhuánbāosùaliánhéxióngjīsùyīxiànzhìliáoshūxuèyīlàifēizhòngxíngzàishēngzhàngàixìngpínxuèdeliáoxiàobǐjiàodānzhōngxīnhuígùxìngyánjiū